Advancing Oncology Through Peer-Reviewed Research
- Women's Cancer Research Foundation
- 1 day ago
- 5 min read
Published Contributions from Women’s Cancer Research Foundation Leadership
Progress in oncology does not occur in isolation. It advances through rigorous investigation, peer-reviewed publication, and the responsible evaluation of emerging therapies and prevention strategies.
In 2025, leadership from the Women’s Cancer Research Foundation (WCRF), including Founder and Chairman John P. Micha, M.D., and President Bram H. Goldstein, Ph.D., contributed to multiple peer-reviewed publications across respected oncology and medical journals. These works span cancer prevention, therapeutic innovation, and nuanced clinical treatment distinctions in gynecologic oncology.
Together, these publications reflect WCRF’s continued participation in advancing evidence-based cancer care.
Review of Substance Use and Misuse (2025;60(10):1565-1568)
DOI: 10.1080/10826084.2025.2487985PMID: 40200569
As vaping continues to be marketed as a safer alternative to traditional cigarettes, this review critically evaluated the available literature on electronic cigarettes as a smoking cessation strategy.
After conducting an extensive PubMed analysis, the study concluded that:
E-cigarettes are potentially carcinogenic
They may cause significant cardiopulmonary effects
Evidence supporting their effectiveness for smoking cessation remains inconclusive
Long-term safety and nicotine addiction risks remain concerning
The authors advised caution, particularly among vulnerable populations such as teenagers and young adults, who may be disproportionately influenced by vaping marketing.
Why This Matters
Cancer prevention begins before diagnosis. Evaluating public health trends such as vaping is essential in mitigating future cancer burden. By contributing to this review, WCRF leadership helped clarify a rapidly evolving public health issue with direct implications for long-term cancer risk.
Journal of Oncology Pharmacy Practice (2025;31(7):1145-1149)
DOI: 10.1177/10781552251327596PMID: 40123348
Skin cancer remains one of the most common malignancies worldwide. While sunscreen is widely recommended, variability in formulation and usage patterns complicates its protective efficacy.
This comprehensive review analyzed observational studies, cohort research, and randomized controlled trials evaluating sunscreen’s role in preventing melanoma and non-melanoma skin cancers.
Key findings included:
Reduced incidence of melanoma and squamous-cell carcinoma with consistent sunscreen use
Less pronounced protective effects for basal-cell carcinoma
Efficacy dependent on both sunscreen type and adherence to proper application guidelines
Consideration of potential side effects, including dermal irritation and concerns surrounding certain UV filter compounds
Why This Matters
Prevention research must balance benefit with safety. This publication reinforces evidence-based guidance for clinicians while acknowledging formulation nuances that impact real-world effectiveness.
Anticancer Research (2025;45(7):2711-2717)
DOI: 10.21873/anticanres.17641PMID: 40578947
While early-stage endometrial cancer often carries favorable outcomes, advanced or recurrent disease remains significantly more challenging.
This review evaluated emerging data surrounding immunotherapy in combination with chemotherapy for advanced-stage or recurrent endometrial carcinoma, with particular attention to mismatch repair status (dMMR vs pMMR).
Findings highlighted:
Improved progression-free survival with immunotherapy combinations
Strong survival data associated with dostarlimab in both dMMR and pMMR patients
Extended follow-up data suggesting durable clinical benefit
Meaningful distinctions between available agents including pembrolizumab and durvalumab
Why This Matters
Understanding therapeutic differentiation is critical in modern oncology. By contributing to this review, WCRF leadership helped clarify evolving immunotherapy strategies that directly impact women facing advanced endometrial cancer.
Expert Review of Anticancer Therapy (2025;25(6):593-597)
DOI: 10.1080/14737140.2025.2496519PMID: 40249727
Although first-line chemotherapy produces favorable initial response rates in ovarian cancer, five-year overall survival remains concerning. The inclusion of PARP inhibitors following induction chemotherapy has transformed treatment paradigms.
This review examined clinical distinctions among:
Olaparib
Niraparib
Rucaparib
Key conclusions included:
Treatment response varies according to homologous recombination deficiency (HRD) status
Only olaparib (alone or with bevacizumab) has demonstrated consistent five-year overall survival benefit
Tolerability profiles and regulatory distinctions differ among agents
Why This Matters
Precision oncology requires precision interpretation. Clarifying outcome differences among PARP inhibitors empowers clinicians to tailor therapy according to tumor biology and patient characteristics.
A Continuum of Oncology Research: Prevention to Advanced Therapeutics
Taken together, these publications illustrate the breadth of WCRF leadership involvement in oncology discourse:
Public health risk evaluation (vaping)
Cancer prevention strategies (sunscreen)
Immunotherapy advancement in endometrial carcinoma
Molecularly guided therapy in ovarian cancer
This continuum reflects a commitment not only to treating cancer — but to understanding its prevention, progression, and evolving therapeutic landscape.
Why Peer-Reviewed Participation Matters
Participation in peer-reviewed medical journals ensures:
Scientific rigor
Transparency of analysis
Independent validation
Contribution to global oncology standards
For donors and partners, this demonstrates that Women’s Cancer Research Foundation leadership remains actively engaged in shaping contemporary cancer care, not merely observing it.
Research requires sustained investment. Each publication represents collaboration, data evaluation, and a commitment to improving outcomes for women facing cancer.
Support Continued Oncology Research
Advancing prevention, refining treatment, and improving survival outcomes depend on ongoing research efforts.
Together, we move oncology forward.
FAQs About WCRF’s Published Oncology Research
1. What role does the Women’s Cancer Research Foundation play in peer-reviewed medical research?
The Women’s Cancer Research Foundation actively contributes to peer-reviewed oncology publications through the work of its leadership and affiliated researchers. Founder and Chairman John P. Micha, M.D., and President Bram H. Goldstein, Ph.D., participate in literature reviews, clinical evaluations, and therapeutic analyses that are published in established medical journals. These contributions support evidence-based cancer prevention and treatment strategies.
2. Why is peer-reviewed publication important in cancer research?
Peer-reviewed publication ensures that research undergoes independent evaluation by experts before being accepted into medical literature. This process strengthens scientific integrity, promotes transparency, and ensures that conclusions are supported by credible data. Participation in peer-reviewed journals demonstrates active engagement in advancing oncology standards of care.
3. How does WCRF’s published research impact patient care?
The research contributions highlighted in these publications address both cancer prevention and advanced therapeutic strategies. Topics such as vaping-related carcinogenic risk, sunscreen efficacy, immunotherapy in endometrial cancer, and PARP inhibitor distinctions in ovarian cancer directly inform clinical decision-making and patient counseling.
4. What is the significance of research on immunotherapy for endometrial cancer?
Immunotherapy combined with chemotherapy has improved progression-free survival in patients with advanced or recurrent endometrial carcinoma, particularly in those with mismatch repair deficiency (dMMR). By reviewing and analyzing these evolving treatment approaches, WCRF leadership contributes to clarifying therapeutic distinctions that may influence patient outcomes.
5. Why are PARP inhibitors important in ovarian cancer treatment?
PARP inhibitors have significantly altered the treatment landscape in advanced-stage ovarian cancer, particularly for patients with homologous recombination deficiency (HRD). Research evaluating clinical differences among available PARP inhibitors helps refine treatment selection and improve long-term survival strategies.
6. Does WCRF only focus on treatment research?
No. WCRF’s published contributions span the full continuum of cancer care, including prevention strategies such as smoking cessation evaluation and sunscreen efficacy research. Addressing risk factors and early prevention remains an essential component of reducing cancer burden.
7. How does this research benefit donors and supporters?
Donor support enables continued participation in meaningful research efforts that contribute to global oncology knowledge. Published research reflects sustained engagement in advancing evidence-based cancer care, reinforcing the foundation’s commitment to improving outcomes for women facing cancer.
8. Where can I access the journals referenced in these publications?
Each publication includes a DOI and PubMed identifier, allowing readers to access abstracts and journal information directly through medical databases and journal websites. These references ensure transparency and allow independent review of the research findings.
About Women’s Cancer Research Foundation:
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Comments